• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

首发非情感性精神病后临床缓解的预测因素:社会人口学、发病前和临床变量。

Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.

机构信息

University Hospital La Fe, Department of Psychiatry, Valencia, Spain.

出版信息

Psychiatry Res. 2013 Apr 30;206(2-3):181-7. doi: 10.1016/j.psychres.2012.10.011. Epub 2012 Nov 14.

DOI:10.1016/j.psychres.2012.10.011
PMID:23159063
Abstract

The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remission. The logistic regression analysis revealed that the strongest predictors of achieving clinical remission 1 year away from a first episode of non-affective psychosis were the length of duration of untreated psychosis (DUP), the severity of negative symptomatology and the educational level attained at baseline. The results suggest that: (1) patients with a lengthy DUP, a greater severity of negative symptomatology at baseline and with a lower education level are in a higher risk of not achieving a clinical remission during the first year of treatment; and (2) early intervention clinical programs should aim to reduce the length of DUP in order to provide a better outcome for patients.

摘要

这项研究的目的是确定与疾病首次发作后 1 年内临床缓解可能性降低相关的预测因素。研究纳入了 174 名连续的首发患者,这些患者之前均未接受过抗精神病药物治疗。患者被随机分配至氟哌啶醇、奥氮平或利培酮组,进行开放性、前瞻性临床试验。主要的结局变量是由精神分裂症缓解工作组制定的缓解标准。为了预测 1 年后的缓解状态,将临床变量纳入逻辑回归分析中。1 年后,31%的患者符合缓解标准。逻辑回归分析显示,预测首发非情感性精神病 1 年后达到临床缓解的最强预测因素是未治疗精神病持续时间(DUP)的长短、阴性症状的严重程度和基线时的受教育程度。结果表明:(1)DUP 较长、基线时阴性症状较严重且受教育程度较低的患者,在治疗的第一年达到临床缓解的风险较高;(2)早期干预临床方案应旨在缩短 DUP,为患者提供更好的预后。

相似文献

1
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.首发非情感性精神病后临床缓解的预测因素:社会人口学、发病前和临床变量。
Psychiatry Res. 2013 Apr 30;206(2-3):181-7. doi: 10.1016/j.psychres.2012.10.011. Epub 2012 Nov 14.
2
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.首发非情感性精神病患者急性治疗反应的预测因素:社会人口统计学、病前及临床变量
J Psychiatr Res. 2007 Oct;41(8):659-66. doi: 10.1016/j.jpsychires.2006.05.002. Epub 2006 Jun 23.
3
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.首发非情感性精神病患者抗精神病治疗短期反应中症状维度的轨迹。
Psychol Med. 2014 Jan;44(1):37-50. doi: 10.1017/S0033291713000330. Epub 2013 Mar 6.
4
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.首发非情感性精神病的复发预防和缓解:氟哌啶醇、利培酮和奥氮平的随机、对照、1 年随访比较。
J Psychiatr Res. 2011 Jun;45(6):763-9. doi: 10.1016/j.jpsychires.2010.11.002. Epub 2010 Nov 23.
5
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.氟哌啶醇、利培酮和奥氮平治疗首发非情感性精神病的疗效:一项随机、灵活剂量、开放性、1 年随访比较的结果。
J Psychopharmacol. 2011 Jun;25(6):744-54. doi: 10.1177/0269881110388332. Epub 2011 Feb 3.
6
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.氟哌啶醇、利培酮和奥氮平治疗首发精神病的神经认知有效性:一项随机对照1年随访比较研究
J Clin Psychiatry. 2009 Apr 21;70(5):717-29. doi: 10.4088/JCP.08m04634.
7
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.首发精神分裂症、分裂情感性障碍和精神分裂症样障碍患者抗精神病治疗反应的预测因素。
Br J Psychiatry. 2004 Jul;185:18-24. doi: 10.1192/bjp.185.1.18.
8
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.利培酮与氟哌啶醇治疗首发精神病:一项长期随机试验
Am J Psychiatry. 2005 May;162(5):947-53. doi: 10.1176/appi.ajp.162.5.947.
9
Olanzapine versus haloperidol treatment in first-episode psychosis.奥氮平与氟哌啶醇治疗首发精神病的比较。
Am J Psychiatry. 1999 Jan;156(1):79-87. doi: 10.1176/ajp.156.1.79.
10
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.首发精神分裂症患者急诊入院并接受基于算法的药物治疗时缓解的预测因素:一项观察性研究的二次分析。
Early Interv Psychiatry. 2019 Jun;13(3):589-597. doi: 10.1111/eip.12531. Epub 2017 Dec 12.

引用本文的文献

1
Criminal Offending and Incarceration in United States Adults With Early Phase Psychosis and Comorbid Substance Use Disorder.美国患有早期精神病和共病物质使用障碍的成年人的犯罪与监禁情况
Early Interv Psychiatry. 2025 Feb;19(2):e70005. doi: 10.1111/eip.70005.
2
Comorbid anxiety, loneliness, and chronic pain as predictors of intervention outcomes for subclinical depressive symptoms in older adults: evidence from a large community-based study in Hong Kong.焦虑、孤独和慢性疼痛共病与老年人亚临床抑郁症状干预结果的关系:来自香港一项大型社区研究的证据。
BMC Psychiatry. 2024 Nov 21;24(1):839. doi: 10.1186/s12888-024-06281-2.
3
Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning.
一项评估第二代抗精神病药治疗精神分裂症的停药、缓解和社会功能的随机、开放标签研究:JUMPs 研究的 104 周最终结果。
BMC Psychiatry. 2024 Sep 5;24(1):600. doi: 10.1186/s12888-024-06031-4.
4
Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders.氟哌啶醇(口服)与奥氮平(口服)治疗精神分裂症及精神分裂症谱系障碍患者。
Cochrane Database Syst Rev. 2024 Jul 3;7(7):CD013425. doi: 10.1002/14651858.CD013425.pub2.
5
Effects of Adherence to Pharmacological Treatment on the Recovery of Patients with Schizophrenia.坚持药物治疗对精神分裂症患者康复的影响。
Healthcare (Basel). 2021 Sep 18;9(9):1230. doi: 10.3390/healthcare9091230.
6
Prediction of Early Symptom Remission in Two Independent Samples of First-Episode Psychosis Patients Using Machine Learning.基于机器学习对首发精神病患者的两个独立样本的早期症状缓解进行预测。
Schizophr Bull. 2022 Jan 21;48(1):122-133. doi: 10.1093/schbul/sbab107.
7
Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review.首发精神病治疗抵抗的预测因素:一项系统综述
Front Psychiatry. 2019 Feb 26;10:67. doi: 10.3389/fpsyt.2019.00067. eCollection 2019.
8
A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia.精神分裂症患者中基因变异与奥氮平早期反应相关性的初步研究。
Indian J Psychiatry. 2018 Jan-Mar;60(1):10-16. doi: 10.4103/psychiatry.IndianJPsychiatry_104_18.
9
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.首发非情感性精神病治疗的当前数据及临床见解:一项综述
Neurol Ther. 2016 Dec;5(2):105-130. doi: 10.1007/s40120-016-0050-8. Epub 2016 Aug 23.
10
Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.使用第二代抗精神病药物治疗的早期精神分裂症谱系障碍和未另行指定的精神病青年的结局:一项前瞻性、自然队列研究的12周结果
J Child Adolesc Psychopharmacol. 2015 Sep;25(7):535-47. doi: 10.1089/cap.2014.0164.